Cipla and Formosa Partner for Multi-Regional Licensing Deal on Clobetasol Suspension

Cipla Limited and Taiwan-based Formosa Pharmaceuticals have signed a landmark multi-regional licensing agreement for the commercialization of APP13007, a clobetasol propionate ophthalmic suspension (0.05%). This innovative treatment, approved by the USFDA, targets post-operative inflammation and pai...

Cipla Limited and Taiwan-based Formosa Pharmaceuticals have signed a landmark multi-regional licensing agreement for the commercialization of APP13007, a clobetasol propionate ophthalmic suspension (0.05%). This innovative treatment, approved by the USFDA, targets post-operative inflammation and pain following ocular surgery. Cipla will exclusively market the product across 11 countries, including India, South Africa, Malaysia, and Argentina. APP13007 offers a convenient twice-daily dosing regimen for 14 days without tapering, providing rapid relief from inflammation and pain. The deal includes upfront payments, royalties, and milestone considerations. Cipla’s Global COO Achin Gupta emphasized the partnership's significance in expanding Cipla's ophthalmology portfolio. Formosa’s President Erick Co expressed confidence in Cipla’s ability to bring this novel therapy to patients worldwide. This collaboration marks a significant advancement in ophthalmic care. Source: PR Newswire.